STOCK TITAN

BioAffinity Technologies Inc - BIAFW STOCK NEWS

Welcome to our dedicated news page for BioAffinity Technologies (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on BioAffinity Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioAffinity Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioAffinity Technologies's position in the market.

Rhea-AI Summary
WallachBeth Capital LLC facilitated bioAffinity Technologies, Inc.'s (BIAF) sale of 1,600,000 shares of common stock and common warrants in a registered direct offering and private placement. The combined purchase price was $1.5625 per share, with warrants exercisable at $1.64 per share. WallachBeth Capital acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
offering
-
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF) closes securities purchase agreement with institutional investors, offering 1,600,000 shares of common stock and warrants at $1.5625 per share, expecting $2.5 million in gross proceeds. The company plans to utilize the funds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
offering
-
Rhea-AI Summary
BioAffinity Technologies (BIAF) announces a securities purchase agreement with institutional investors for the sale of 1,600,000 shares of common stock and common warrants. The Offering includes a registered direct offering and a concurrent private placement at a combined purchase price of $1.5625 per common share. The common warrants have an exercise price of $1.64 per share and will expire five years from the date of shareholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
offering
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) has announced a securities purchase agreement with institutional investors for the sale of 1,600,000 shares of common stock and common warrants. The purchase price is $1.5625 per share, with warrants exercisable at $1.64 per share. The offering includes a registered direct offering and a concurrent private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
offering
-
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) reports a 375% growth in CyPath® Lung tests ordered and processed over the past three months. The company attributes this growth to the introduction of a reimbursement code, completion of branding, and expansion of the sales force. The successful integration of the commercial laboratory has also contributed to the increasing physician interest and adoption of the noninvasive test for early-stage lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.66%
Tags
none
-
News
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF) announces significant developments, including the addition of CyPath® Lung test to Lung Innovations Network, expansion of sales team, addition of Dr. Sandeep Bansal to advisory board, and participation in American Thoracic Society's conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has announced the addition of Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, to the company's team. The company is focused on noninvasive tests for early-stage cancer detection, including CyPath® Lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
management
-
News
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has recently achieved CAP accreditation for its Precision Pathology Laboratory Services, received a patent in India for targeted cancer treatment, and has been collaborating with ScienceSoft. The company's subsidiary, OncoSelect Therapeutics, LLC, has expanded its intellectual property portfolio to 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
bioAffinity Technologies, Inc. has been granted a patent in India for porphyrin compounds used in targeted cancer treatment. This patent adds to the company's existing patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications. The company's first product, CyPath® Lung, is a noninvasive diagnostic test for early-stage lung cancer, utilizing advanced flow cytometry and artificial intelligence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
News
Rhea-AI Summary
SAN ANTONIO announces partnership with XYZ Pharmaceuticals to develop new cancer treatment - Ticker Symbol: SA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
BioAffinity Technologies Inc

Nasdaq:BIAFW

BIAFW Rankings

BIAFW Stock Data

5.97M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Antonio

About BIAFW

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.